New glimpses of caveolin-1 functions in embryonic development and human diseases

Saijun MO1, Shengli YANG1, Zongbin CUI (✉)2

1 Department of Basic Oncology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China; 2 Key Laboratory of Biodiversity and Conservation of Aquatic Organism, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2011

Abstract Caveolin-1 (Cav-1) isoforms, including Cav-1α and Cav-1β, were identified as integral membrane proteins and the major components of caveolae. Cav-1 proteins are highly conserved during evolution from Caenorhabditis elegans to human and are capable of interacting with many signaling molecules through their caveolin scaffolding domains to regulate the activities of multiple signaling pathways. Thus, Cav-1 plays crucial roles in the regulation of cellular proliferation, differentiation and apoptosis in a cell-specific and contextual manner. In addition, Cav-1 is essential for embryonic development of vertebrates owing to its regulation of BMP, Wnt, TGF-β and other key signaling molecules. Moreover, Cav-1 is mainly expressed in terminally differentiated cells and its abnormal expression is often associated with human diseases, such as tumor progression, cardiovascular diseases, fibrosis, lung regeneration, and diseases related to virus. In this review, we will further discuss the potential of Cav-1 as a target for disease therapy and multiple drug resistance.

Keywords Caveolin-1, signal transduction, embryonic development, human diseases

Introduction

Caveolae are flask-shaped vesicular invaginations of plasma membrane with diameters of 50–100 nm (Yamada, 1955). Important components of caveolae include three identified caveolin members: Cav-1, -2 and -3. Cav-1 was identified as an integral membrane protein and the major molecular marker for caveolae (Rothberg et al., 1992). Cav-1 and -2 are co-expressed in almost all tissues except lymphocytes, while Cav-3 expression is limited to striated muscles (Head and Insel, 2007). Cav-1 contains several functional domains that are necessary for its roles in cell surface signaling, endocytosis and cholesterol transport (Table 1 and Fig. 1).

Cav-1 isoforms, including Cav-1α and Cav-1β, are translated from two distinct mRNAs and contain a hydrophobic stretch of amino acids, a scaffolding domain, and an acylated C-terminal region, but only Cav-1α contains the N-terminal 31 amino acids (Kogo and Fujimoto, 2000; Scherer et al., 1995). The tyrosine(Y) 14 in Cav-1α was identified as a phosphorylation site, while this site does not exist in Cav-1β (Li et al., 1996). Phosphorylated tyrosine 14 is thought to be a specific tyrosine kinase substrate (Lee et al., 2000) and is associated with cell (including tumor cell) migration (Joshi et al., 2008). It has been shown that Cav-1α and -1β have different subcellular distributions (Scherer et al., 1995; Kogo et al., 2004) and play distinct roles in caveolae formation (Fujimoto et al., 2000) and development of lung and liver (Kogo et al., 2004; Wang et al., 2010a). In addition, Cav-1α and-1β show different activities in regulation of BMP and phosphatidylinositol 3-kinase (PI3K)/Akt signaling (Ono et al., 2004; Nohe et al., 2005). Cav-1 proteins have important roles in vesicular transport, cholesterol homeostasis and signal transduction and biochemically interacting with many signaling cascades in multiple signaling pathways to regulate cellular proliferation, differentiation and apoptosis in a cell-specific and contextual manner (Cohen et al., 2004). In this review, we will focus on the recent understanding of Cav-1 functions in signal transduction, embryonic development and human diseases.
Caveolin-1 and signal transduction

The scaffolding domain of Cav-1 (CSD) can recognize and bind proteins containing the sequence motif \( \Phi x\Phi x\Phi x\Phi \), \( \Phi xxx\Phi xx\Phi \) or \( \Phi x\Phi xxx\Phi xx\Phi \), where \( \Phi \) is an aromatic residue and \( x \) is any amino acid (Couet et al., 1997). Through the CSD, Cav-1 interacts with a number of growth factor receptors such as transforming growth factor-\( \beta \) receptor (TGF-\( \beta \)R), fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), insulin-like growth factor receptor (IGFR), platelet-derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR), and signal molecules including H-ras, G protein, eNOS, \( \beta \)-catenin and p53 (Table 2) (Liu et al., 2002). It is well known that roles of Cav-1 in the regulation of cellular proliferation, differentiation and apoptosis are closely associated with this CSD domain.

Mechanistically, Cav-1 is able to control activities of multiple signaling pathways by its participation in the internalization of growth factor receptors and transcriptional factors. In general, Cav-1 acts as a negative regulator to control the basal activity of many signaling molecules. For example, Cav-1 inhibits activities of growth factor receptors (e.g. EFGR, PDGFR, IGFR and FGFR), the downstream mitogen-activated protein kinase (MAPK), PI3K/Akt and Wnt signaling (Han et al., 2009; Matthews et al., 2008; Cabrita et al., 2006; Galbiati et al., 2000). However, Cav-1 sometimes plays distinct roles in a signaling pathway through interaction with different signal molecules. For instance, Cav-1 suppresses the TGF-\( \beta \)-mediated transcriptional activity through direct interaction with ubiquitous TGF-\( \beta \)R (Razani et al., 2001a; Lee et al., 2007), but enhances the TGF-\( \beta \)/ALK1 signaling as shown by its activation of ALK1 (an activin receptor-like kinase and TGF-\( \beta 1 \)R) -specific reporters (Santibanez et al., 2008). Moreover, Cav-1 expression leads to the accumulation of \( \beta \)-catenin within caveolae membranes and thus inhibits the \( \beta \)-catenin/Lef-1 signaling activated by wnt-1 or the overexpression of \( \beta \)-catenin itself (Galbiati et al., 2000), while inducing LRP6 (a low-density lipoprotein receptor-related protein 6 and wnt receptor) internalization and activating wnt/\( \beta \)-catenin signaling (Yamamoto et al., 2000).

### Table 1 Caveolin-1 structure and domain functions

| Domain locations | Names | Known functions | References |
|------------------|-------|----------------|------------|
| 14               | Tyrosine 14 | Phosphorylation and caveolae internalization | Sun et al., 2007 |
| 46-55            | Polarization domain (PD) | Cav-1 polarization and caveolae formation | Sun et al., 2007 |
| 68-75            | Signature domain (SD) | Release Caveolin-1 from endoplasmic reticulum | Machleidt et al., 2000 |
| 61-101           | Oligomerization domain (OD) | Oligomerization with himself or Cav-2 | Sargiacomo et al., 1995; Scherer et al., 1997 |
| 82-101           | Circular dichroism (CD) | Stabilize CSD helical conformation | Le Lan et al., 2006 |
|                  | N-attachment domain (N-MAD) | Attach with membrane | Schlegel and Lisanti, 2000 |
|                  | Caveolin Scaffolding domain (CSD) | Interact with other protein | Couet et al., 1997 |
| 82–109           | Nuclear magnetic resonance (NMR) | Solution of phosphatidylserine | Le Lan et al., 2006 |
| 102–134          | Intramembrane region (IMR) | Plasma membrane location | Glenney and Soppet, 1992 |
| 135–150          | C-attachment domain (C-MAD) | Attachment with membrane | Schlegel and Lisanti, 2000 |
| 133, 143, 156    | Cysteine | Palmitoylation | Dietzen et al., 1995 |
|                  |         | Interaction with other acylated protein | Lee et al., 2001 |
|                  |         | Bind and transport cholesterol | Uittenbogaard and Smart, 2000 |

Figure 1 A structural model of Cav-1 protein (178 amino acids) from Head and Insel (2007) with some modifications. PD: polarization domain; C-MAD: C-attachment domain; IMR: intramembrane region; NMR: nuclear magnetic resonance; CSD: Caveolin Scaffolding domain; N-MAD: N-attachment domain; CD: circular dichroism; SD: signature domain; OD: oligomerization domain; Y14: tyrosine 14.
Furthermore, Cav-1 inhibits EGF signaling by direct interaction with EGFR (Couet et al., 1997), but promotes EGF signaling in a breast cancer cell line, MCF-7 (Agelaki et al., 2009). Thus, Cav-1 appears to control the activity of

| Molecules | Interact | Substrate | Regulate | Signaling pathway | Reference |
|-----------|----------|-----------|----------|-------------------|-----------|
| Growth factor receptors | | | | | |
| TGFR | Directly | most of TβR | Suppress | TGF-β | Razani et al., 2001a |
| | Directly | ALK1 | Promote | TGF-β | Santibanez et al., 2008 |
| | Directly | BRII | inhibit (β isoform) | BMP | Nohe et al., 2005 |
| EGFR | Directly | EGFR | inhibit | EGFR | Coupe et al., 1997 |
| | Indirectly | EGFR | inhibit | EGFR-MAPK | Han et al., 2009 |
| | Directly | EGFR | promote | EGFR | Agelaki et al., 2009 |
| FGFR | Directly | Sprouty1-4 | inhibit | p42/44 MAPK | Cabrita et al., 2006 |
| IR | Directly | IR | Active | Insulin | Nystrom et al., 1999 |
| | Directly | IRS-1 | active | Insulin | Chen et al., 2008 |
| IGFR | Directly | IGF-IR | upregulate | IGF | Ravid et al., 2005 |
| VEGFR | Directly | VEGFR-2 | no action | VEGF | Labrecque et al., 2003 |
| | Directly | VEGF-2 | inhibit | p42/44 MAPK | Fang et al., 2007 |
| | Directly | Elk-1 | block | VEGF | Liu et al., 1999 |
| PDGFR | Indirectly | PDGFR | inhibit | PDGF | Tamai et al., 2001 |
| TNFR | Directly | TRAIL | Negatively | – | Zhao et al., 2009 |
| | Directly | TRAF2 | Active | – | Feng et al., 2001 |
| Growth factors | | | | | |
| EGF | Indirectly | EGF | Inhibit | p42/44 MAPK | Zhang et al., 2000 |
| | – | EGF | Inhibit | PI3K/Akt | Park and Han, 2009 |
| IGF | Directly | IGF-I | Deficiency Promote | PI3K/Akt | Matthews et al., 2008 |
| PDGF | Directly | PDGF | Inhibit | PDGF | Peterson et al., 2003 |
| TNF | Directly | TNFα | Negative | MKK3/p38 MAPK | Wang et al., 2006 |
| VEGF | – | VEGF | Stabilize | PI3K/Akt | Li et al., 2009 |
| TGF | – | TGF-β1 | Stabilize | PI3K/Akt | Li et al., 2009 |
| FGF | – | FGF2 | Stabilize | PI3K/Akt | Li et al., 2009 |
| Transcriptional factors | | | | | |
| β-catenin | Directly | β-catenin | Inhibit | Wnt | Galbiati et al., 2000 |
| | Indirectly | Survivin | Inhibit | Wnt | Torres et al., 2006 |
| | Indirectly | COX-2 | Inhibit | Wnt | Rodriguez et al., 2009 |
| | Directly | LRP6 | Active | Wnt | Yamamoto et al., 2006 |
| NF-κB | Directly | TNFα | Negative | PI3K/PKB and p44/42 MAPK | Fakhraziadeh et al., 2008 |
| | – | – | Active | – | Garreau et al., 2006 |
| p53 | Directly | Mdm2 | Stabilize | p53/p21 (Waf1/Cip1) | Bartholomew et al., 2009 |
| | – | p53 | Inhibit | – | Linge et al., 2007 |
| | Indirectly | p53 | Inhibit | IGF | Ravid et al., 2005 |
| | Directly | MEK-1, ERK-2 | – | p42/44 MAPK | Engelman et al., 1998a |

Abbreviations: EGF: epidermal growth factor; TNF: tumor necrosis factor; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor; IGF: insulin-like growth factor; FGF2: basic fibroblast growth factor; TGF: transforming growth factor; EGFR: epidermal growth factor receptor; TNFR: tumor necrosis factor receptor; PDGFR: platelet-derived growth factor receptor; VEGFR: vascular endothelial growth factor receptor; FGFR: fibroblast growth factor receptor; TGF: transforming growth factor receptor; IGFR: insulin-like growth factor receptor; TNFR: tumor necrosis factor receptor type II; IR: insulin receptor; IGFR: insulin-like growth factor receptor; IRS-1: insulin receptor substrate-1; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand; TRAF2: tumor necrosis factor (TNF) receptor-associated factor 2; COX-2: cyclooxygenase-2; BMP: Bone morphogenetic proteins; MKK3/p38 MAPK: mitogen-activated protein kinase kinase 3/p38 mitogen-activated protein kinase; PI3K/Akt: phosphatidylinositol 3-kinase/Akt; NF-κB: nuclear factor kappa B; PI3K-PKB: PI3K/protein kinase B; MEK-1: MAP kinase/ERK kinase 1; LRP6: low-density lipoprotein receptor-related protein 6; ALK1: activin receptor-like kinase 1; Elk-1: Ets-like protein 1;”–” indicates “no clear statement”
multiple signaling pathways in a cell-specific and contextual manner.

In addition, it has been shown that Src-mediated phosphorylation of Cav-1α on Y14 is required for stretch-induced EGFR and Akt activation in mesangial cells (Zhang et al., 2006). Phosphorylation of this site is also implicated in other signaling responses including TGF-β (Peng et al., 2008) and IGF (Chen et al., 2008) signaling.

Caveolin-1 and embryonic development of vertebrates

Cav-1 proteins exist in a wider range of eukaryotic systems including nematodes Caenorhabditis elegans (Tang et al., 1997) and Trichinella spiralis (Hernández-Bello et al., 2008), frog Xenopus laevis (Razani et al., 2002), zebrafish Danio rerio (Fang et al., 2006), pig (Wang et al., 2008), mouse (Engelman et al., 1998b) and human (Engelman et al., 1999). Amino acid sequence alignment reveals that Cav-1 proteins are highly conserved from Caenorhabditis elegans to human (Frank and Lisanti, 2006; Wang et al., 2010a), suggesting conserved physiological and/or developmental functions of Cav-1 during evolution.

It has been shown that Cav-1 is expressed in germ cells during embryonic development from nematode to human. For example, Cav-1 is expressed in most cells throughout embryonic and larval development of C. elegans and is essential for Ras/MAP-kinase-dependent progression through the meiotic cell cycle (Scheel et al., 1999). In zebrafish, cav-1 mRNAs are detected during the very early stages of development (Fang et al., 2006). Cav-1 is also expressed in oocytes of C. elegans (Scheel et al., 1999) and a high level of cav-1 mRNA was detected in the developing ovaries but not testes of mouse (Bullejos et al., 2002). In addition, expression of Cav-1 is detected in oocytes and embryos and plays a role in oocyte maturation and embryogenesis of Trichinella spiralis (Hernández-Bello et al., 2008). These data suggest that Cav-1 may play important roles in embryonic development of vertebrates. Indeed, multiple lines of evidence indicate that Cav-1 is able to modulate activities of key developmental signaling pathways including TGF-β, BMP, Wnt and MAPK (Razani et al., 2001a; Nohe et al., 2005; Scheel et al., 1999). However, Cav-1 null mice are viable and fertile (Drab et al., 2001; Razani et al., 2001b), although they display some distinguishable phenotypes including loss of invaginated caveolae, vascular and skeletal muscle abnormalities, thickened alveolar septa, dilated cardiomyopathy, reduction in life span, leanness, and resistance to diet-induced obesity (Cohen et al., 2003; Schubert et al., 2007). Therefore, the detailed developmental progression of the Cav-1-deficient mouse embryos has yet to be defined (Frank and Lisanti, 2006).

Current knowledge about functions of Cav-1 during embryonic development mainly comes from research using zebrafish. During zebrafish embryogenesis, transcripts of Cav-1 are mainly found in Kupffer’s vesicle, tailbud, intersomite boundaries, heart, branchial arches, pronephric ducts and peritrichium (Fang et al., 2006; Frank and Lisanti, 2006; Nixon et al., 2007). In contrast to Cav-1 null mice, knockdown of Cav-1 expression leads to lethal zebrafish embryos, which could result from major reduction of caveolae numbers on the cellular membrane, abnormal anterior-posterior (AP) patterning, severe disruption of actin cytoskeleton, defects in development of somites, and neuromasts (Fang et al., 2006; Frank and Lisanti, 2006; Nixon et al., 2007). Similarly, inhibition of Cav-1 expression by RNAi in embryos of C. elegans leads to early larval lethality (Scheel et al., 1999). Further studies indicate that abnormal phenotypes caused by the absence of each zebrafish cav-1 isoform could be partially rescued by the corresponding human counterpart, suggesting that functions of Cav-1 proteins are highly conserved throughout evolution (Fang et al., 2006; Frank and Lisanti, 2006; Nixon et al., 2007). Recently, we demonstrate that both Wnt and BMP signals act coordinately to negatively control transcriptional expression of cav-1 during embryonic development and provide the first biochemical and genetic evidence that Cav-1 regulates the dorsoventral patterning of zebrafish (Mo et al., 2010).

Cav-1α and -1β exhibit overlapping but distinct expression patterns during embryogenesis of zebrafish. For example, both zebrafish cav-1α and -1β mRNAs are detected in the heart, pharyngeal vasculature, notochord, somites, skin, and neuromast tissues during the very early stages of development, whereas cav-1α mRNA is the only isoform detectable in the intestinal epithelium of late-stage embryos (Fang et al., 2006). Similar expression patterns of Cav-1 are also found in Xenopus laevis (Razani et al., 2002). Additionally, over-expression of Cav-1α could not rescue the phenotype caused by knockdown of Cav-1β isoform in zebrafish and vice versa (Fang et al., 2006), suggesting non-overlapping functions of Cav-1 isoforms. Thus, Cav-1 isoforms appear to play differential roles in a cell- or tissue-specific manner. It is suggested that distinct functions of Cav-1α and -1β are closely associated with the phosphorylation at Y14 in Cav-1α (Frank and Lisanti, 2006).

Caveolin-1 and human diseases

Cav-1 is mainly expressed in terminally differentiated cells such as epithelia, endothelia, adipocytes, fibroblasts and smooth muscle cells (Lisanti et al., 1994). It plays important roles in vesicular transport, cholesterol homeostasis and signal transduction and is able to biochemically interact with many signaling cascades in multiple signaling pathways to regulate cellular proliferation, differentiation and apoptosis in a cell-specific and contextual manner (Cohen et al., 2004). Therefore, abnormal expression of Cav-1 is often associated with tumor progression (Williams and Lisanti, 2005) and
many other disease-related phenotypes in the lung, vasculature, heart, adipose tissue, and the mammary gland (Cohen et al., 2004; Drab et al., 2001; Fujimoto et al., 2000; Hashimoto et al., 2003; Kasper et al., 1998; Kim et al., 2006; Schwencke et al., 2006).

Caveolin-1 and tumorigenesis

Cav-1 was considered as a key molecule in oncogenic cellular transformation, hyperplasia and metastasis during tumor progression (Juhász et al., 2003) due to its modulation of many signaling pathways in human tumors. In human breast cancer-derived cells, Cav-1 enhances matrix-independent cell survival through upregulation of IGF-IR expression and activation of IGF-I signaling (Ravid et al., 2005). Cav-1 was also found to regulate the activity of EGFR in human glioblastoma, squamous carcinoma and epidermoid carcinoma (Abulrob et al., 2004; Kim and Bertics, 2002). Cav-1 was downregulated in breast, lung, colon, stomach and ovarian cancer, but upregulated in prostate, kidney and breast cancer (reviewed by Williams and Lisanti, 2005). In addition, Cav-1 plays distinct roles in different tumor cell types or tumors derived from the same cell type or tissue (Hino et al., 2003; Liu et al., 2002; Scherer et al., 1995). Thus, Cav-1 appears to act as both a tumor suppressor and an oncogene in a contextual manner. Three distinct mechanisms have been proposed to explain why Cav-1 functions either as a tumor suppressor or as an oncogene, depending on the tumor type and/or tumor stage (Williams and Lisanti, 2005). It is known that TGF-β signaling functions are different in the early stage of transformation and carcinogenesis and in the later stage of tumor progression (Williams and Lisanti, 2005). Cav-1 has been shown to interact with the Type I TGF-β receptor and negatively control the activity of TGF-β signaling (Razani et al., 2001a). Therefore, intriguing roles of Cav-1 in tumorigenesis may be partially associated with its regulation of TGF-β signaling activity.

Cancer chemotherapy always leads to the development of multidrug resistance (MDR), a process that is commonly associated with overexpression of P-glycoprotein (P-gp). It has been shown that P-gp is often co-localized with Cav-1 (Belanger et al., 2004). Overexpression of Cav-1 decreases the drug resistance through suppression of MDR1 gene expression since upregulation of Cav-1 in numerous human MDR cancer cells almost abolished expression of P-gp protein (Lavie et al., 1998; Zhu et al., 2004). Additionally, downregulation of Cav-1 by siRNA reduced its interaction with P-gp and enhanced P-gp transport activity; while transfection of a mutant cav-1Y14F decreased the P-gp/Cav-1 interaction (Barakat et al., 2007). These results suggest that regulation of P-gp function by Cav-1 may depend on the phosphorylation of Cav-1. However, expression of caveolin-1 and caveolin-2 in several MDR cell lines were not detectable, indicating that Cav-1 expression is not associated with expression of P-gp or MDR1 mRNA (Davidson et al., 2002). Thus, Cav-1 appears to modulate MDR in a cell-specific and contextual manner.

Cav-1 and cardiovascular diseases

Cav-1 is also expressed in endothelial cells, smooth muscle cells and macrophages, which are known to play key roles in cardiovascular diseases including atherosclerosis, hypertrophy cardiomyopathy (HCM), heart failure, cardiac hypertrophy (Williams and Lisanti, 2004). Several signal transduction pathways, regulated by Cav-1, were associated with fates of those cells. For instance, TGF-β and p42/44 MAPK signaling pathways are involved in vascular remodeling and angiogenesis (Fang et al., 2007; Santibanez et al., 2008). It has been shown that Cav-1 is able to negatively regulate the proliferation of human endothelial cells by inhibition of the activity of VEGFR-2 (KDR) and downstream p42/44 MAP kinase (Fang et al., 2007). In addition, Cav-1 is suggested to control the angiogenic process by potentiation of TGF-β/ALK1 and repression of TGF-β/ALK5 responses (Santibanez et al., 2008). Moreover, Cav-1 holds a dual role toward modulation of proliferation of vascular smooth muscle cells, depending on the stimulus the cells are exposed to (Sedding and Braun-Dullaeus, 2006).

Cav-1 and fibrosis

Fibrosis is the formation or development of excess fibrous connective tissue in an organ or tissue as a reparative or reactive process. Multiple lines of evidence indicate that Cav-1 is closely involved in fibrogenesis of various tissues. Cav-1 was identified as an early indicator of serious type I cell injury during lung fibrogenesis (Kasper et al., 1998) and its CSD motif is responsible for the antifibrotic properties in vitro and in vivo (Tourkina et al., 2008). Depletion of Cav-1 in mice leads to hyperproliferation of embryonic fibroblasts and formation of fibrotic lung (Drab et al., 2001; Galbiati et al., 2001). In fibrotic diseases, decreased Cav-1 expression likely leads to increased deposition of IGFBP-5 (insulin-like growth factor binding protein-5) in the ECM with subsequent reduction in ECM degradation (Yamaguchi et al., 2010). Cav-1 is able to regulate activities of several signaling pathways involved in the pathogenesis of fibrosis. For example, Cav-1 suppresses the activity of TGF-β signaling and participates in the pathogenesis of systemic sclerosis and idiopathic pulmonary fibrosis (Del Galdo et al., 2008). In summary, Cav-1 acts as an inhibitor of fibrogenesis.

Cav-1 and liver regeneration

Liver regeneration is an orchestrated cellular response that coordinates activation, migration and division of various cells (Frank and Lisanti, 2007). Evidence from recent studies indicates that Cav-1 is involved in liver regeneration through regulation of triglyceride accumulation (Fernández et al.,
2006). After a partial hepatectomy (PH), cav-1−/− mice exhibited impaired liver regeneration and low survival. Hepatocytes isolated from cav-1−/− mice showed dramatically reduced lipid droplet accumulation and did not advance through the cell division cycle. Treatment of cav-1−/− mice with glucose, a predominant energy substrate when compared to lipids, drastically increased survival and reestablished progression of the cell cycle. Thus, caveolin-1 plays a crucial role in the coordination of lipid metabolism with the proliferative response occurring in the liver after cellular injury.

In addition, Fernández et al. (2006) found that two coordinated main signaling pathways, a cytokine-mediated pathway and a growth factor-mediated pathway, were affected after PH in cav-1 deficient mice. These signaling cascades include signal transducer and activator of transcription 3 (STAT3), c-myc, and Jun N-terminal kinase (JNK). However, other researchers suggest that Cav-1 is dispensable for liver regeneration since Cav-1 redistributes from the caveola-enriched domain to the noncaveolar fraction after PH and this redistribution mechanism depends on the phosphorylation on tyrosine 14 (Mayoral et al., 2007).

Cav-1 and infectious diseases associated with virus

Cav-1 is not only involved in regulation of homeostatic cellular functions, but also associated with pathogenesis caused by infection of microbes. Zaas et al. (2009) have shown that Cav-1 plays a role in immunity against bacterial pathogens. Here, we will focus on the roles of Cav-1 in regulation of viral pathogens.

Rotavirus (RV) is the major etiologic agent of virally induced gastroenteritis in children and infants worldwide. Mir et al. (2007) found that the RV non-structural protein 4 (NSP4) binding site (residues 114–135) was localized to Cav-1 residues 2–22 and 161–178, at the amino and carboxyl termini, respectively. Cav-1 is also coexpressed with human immunodeficiency virus (HIV) and blocked expression of HIV-1 and HIV-2 (Llano et al., 2002). The inhibition of HIV-1 and HIV-2 expression by Cav-1 is depending on the intramembrane region (IMR), while the 100 most N-terminal amino acids of Cav-1 (including OD and CSD) is dispensable (Llano et al., 2002). Huang et al. (2007) demonstrate that Cav-1 is able to interact with the gp41 of HIV envelope and then modulate HIV-1 envelope-induced bystander apoptosis (Wang et al., 2010b). It is known that overexpression of Cav-1 can reduce HIV production, and in contrast, HIV infection enhances the expression of Cav-1 (Lin et al., 2010). Recently, it is shown that hepatitis B virus (HBV) also requires a Cav-1-mediated entry pathway to initiate productive infection in HepaRG cells (Macovei et al., 2010).

Cav-1 also influences the activity of virus associated with respiratory tract infections. Cai et al. (2003) demonstrate that the severe acute respiratory syndrome coronavirus (SARS-CoV) contains eight caveolin binding sites, which are located in replicase 1AB, spike protein, orf3 protein, and M protein, respectively. Padhan et al. (2007) showed that the caveolin binding sites in orf3a were sufficient for its interaction with Cav-1. In addition, Cav-1 is incorporated into influenza virus. Cav-1 colocalizes with the paramyxovirus parainfluenza virus 5 (PIV-5) nucleocapsid (NP), matrix (M), and hemagglutinin-neuraminidase (HN) proteins and affects the virus assembly and/or budding (Ravid et al., 2010). Moreover, Cav-1 was identified as a cellular partner of human influenza A viruses and pandemic influenza A virus (H1N1) through interaction with the influenza M2 (Sun et al., 2010).

Adult T cell leukemia (ATL) is a T cell malignancy causatively associated with human T cell leukemia virus type 1 (HTLV-1). The viral protein Tax is able to transcriptionally activate Cav-1 through NF-κB and cAMP response elements and then repress TGF-β signaling (Sawada et al., 2010). In several cell lines derived from lung and cervical cancer, human papilloma virus (HPV) E6 viral oncoprotein down-regulates Cav-1 expression via inactivation of p53 and Cav-1 overexpression can partially revert HPV-mediated cell transformation (Razani et al., 2000). Moreover, Smith et al. (2007) have found that HPV31 entry and initiation of early infection events require both Cav-1 and Dynamin 2. Thus, Cav-1 regulates activities of some viruses closely associated with many carcinomas.

Perspectives

Cav-1 is able to regulate activities of key signaling pathways that are involved in embryonic development and human diseases. Knockdown of Cav-1 in zebrafish leads to dorsalization of early embryos and finally results in embryonic lethality, while Cav-1 null mice are viable and fertile. The functional difference of Cav-1 in embryonic development between zebrafish and mouse raises a crucial question as to whether an unidentified compensatory mechanism by other caveolin family members exists during the embryonic development of mice. In addition, tissue-specific expression suggests potential roles of Cav-1 in organogenesis of vertebrates. Given the essential role of Cav-1 in the regulation of liver regeneration, Cav-1 might be a novel player and indicator of wound healing. Moreover, Cav-1 appears to be closely associated with tumorigenesis and MDR development in tumor cells. It will be of great interest to investigate the effects of Cav-1 on activity and regulation of key signaling molecules in pathological contexts. Although multiple lines of evidence indicate that Cav-1 influences activities of bacteria and virus associated with human diseases, it remains largely unknown about the roles of Cav-1 in the process of pathogenesis. Thus, extensive investigation of mechanisms underlying the interactions of Cav-1 with signaling molecules in cells and functional proteins in bacteria and virus will offer plenty of opportunities to design small molecule drugs in the treatment of human
diseases and it is expected that we will witness many exciting new discoveries about Cav-1 functions in the coming years.

References

Abulrob A, Giuseppe S, Andrade M F, McDermid A, Moreno M, Stanimirovic D (2004). Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene, 23(41): 6967–6979

Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, Movroudis D, Georgoulia V, Stourmaras C (2009). Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther, 8(15): 1470–1477

Barakat S, Demeule M, Pilorget A, Régina A, Gingras D, Baggetto L G, Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft F C, Schedl A, Haller H, Kurzchalia T V (2001). Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science, 293(5539): 2449–2452

Engelman J A, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz D S, Lisanti M P (1998a). Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett, 428(3): 205–211

Engelman J A, Zhang X L, Galbiati F, Lisanti M P (1998b). Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cancer Biol Ther, 8(15): 1477–1487

Engelman J A, Zhang X L, Lisanti M P (1999). Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett, 448(2–3): 221–230

Fakhrazadeh L, Laskin J D, Laskin D L (2008). Regulation of caveolin-1 expression, nitric oxide production and tissue injury by tumor necrosis factor-alpha following ozone inhalation. Toxicol Appl Pharmacol, 227(3): 380–389

Fang K, Fu W, Beardsley A R, Sun X, Lisanti M P, Liu J (2007). Overexpression of caveolin-1 inhibits endothelial cell proliferation by arresting the cell cycle at G0/G1 phase. Cell Cycle, 6(2): 199–204

Fang P K, Solomon K R, Zhuang L, Qi M, Mckee M, Freeman M R, Yelic P C (2006). Caveolin-1α and -1ß perform nonredundant roles in early vertebrate development. Am J Pathol, 169(6): 2209–2222

Feng X, Gaeta M L, Madge L A, Yang J H, Bradley J R, Pober J S (2001). Caveolin-1 associates with TRAF2 to form a complex that is recruited to tumor necrosis factor receptors. J Biol Chem, 276(11): 8341–8349

Fernández M A, Albor C, Ingelmo-Torres M, Nixon S J, Ferguson C, Kurzchalia T, Tebar F, Enrich C, Parton R G, Pol A (2006). Caveolin-1 is essential for liver regeneration. Science, 313(5793): 1628–1632

Frank P G, Lisanti M P (2006). Zebrafish as a novel model system to study the function of caveolae and caveolin-1 in organismal biology. Am J Pathol, 169(6): 1910–1912

Frank P G, Lisanti M P (2007). Caveolin-1 and liver regeneration: role in proliferation and lipogenesis. Cell Cycle, 6(2): 115–116

Fujiyama T, Kogo H, Nomura R, Ume T (2000). Isoforms of caveolin-1 and caveolar structure. J Cell Sci, 113(Pt 19): 3517–3525

Galbiati F, Volonte D, Liu J, Capozza F, Frank P G, Zhu L, Pestell R G, Lisanti M P (2001). Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol Biol Cell, 12(8): 2229–2244

Dietzen D J, Hastings W R, Lublin D M (1995). Caveolin is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of caveolin to caveolae. J Biol Chem, 270(12): 6838–6842

Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft F C, Schedl A, Hailer H, Kurzchalia T V (2001). Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science, 293(5539): 2449–2452

Engelman J A, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz D S, Lisanti M P (1998a). Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett, 428(3): 205–211

Engelman J A, Zhang X L, Galbiati F, Lisanti M P (1998b). Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cancer Biol Ther, 8(15): 1477–1487

Engelman J A, Zhang X L, Lisanti M P (1999). Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett, 448(2–3): 221–230

Fakhrazadeh L, Laskin J D, Laskin D L (2008). Regulation of caveolin-1 expression, nitric oxide production and tissue injury by tumor necrosis factor-alpha following ozone inhalation. Toxicol Appl Pharmacol, 227(3): 380–389

Fang K, Fu W, Beardsley A R, Sun X, Lisanti M P, Liu J (2007). Overexpression of caveolin-1 inhibits endothelial cell proliferation by arresting the cell cycle at G0/G1 phase. Cell Cycle, 6(2): 199–204

Fang P K, Solomon K R, Zhuang L, Qi M, Mckee M, Freeman M R, Yelic P C (2006). Caveolin-1α and -1ß perform nonredundant roles in early vertebrate development. Am J Pathol, 169(6): 2209–2222

Feng X, Gaeta M L, Madge L A, Yang J H, Bradley J R, Pober J S (2001). Caveolin-1 associates with TRAF2 to form a complex that is recruited to tumor necrosis factor receptors. J Biol Chem, 276(11): 8341–8349

Fernández M A, Albor C, Ingelmo-Torres M, Nixon S J, Ferguson C, Kurzchalia T, Tebar F, Enrich C, Parton R G, Pol A (2006). Caveolin-1 is essential for liver regeneration. Science, 313(5793): 1628–1632

Frank P G, Lisanti M P (2006). Zebrafish as a novel model system to study the function of caveolae and caveolin-1 in organismal biology. Am J Pathol, 169(6): 1910–1912

Frank P G, Lisanti M P (2007). Caveolin-1 and liver regeneration: role in proliferation and lipogenesis. Cell Cycle, 6(2): 115–116

Fujiyama T, Kogo H, Nomura R, Ume T (2000). Isoforms of caveolin-1 and caveolar structure. J Cell Sci, 113(Pt 19): 3517–3525

Galbiati F, Volonte D, Brown A M, Weinstein D E, Ben-Ze’ev A, Pestell R G, Lisanti M P (2000). Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae. J Biol Chem, 275(30): 23368–23377

Galbiati F, Volonté D, Liu J, Capozza F, Frank P G, Zhu L, Pestell R G, Lisanti M P (2001). Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol Biol Cell, 12(8): 2229–2244
Garreau S, Gao X P, Brovkovych V, Shimizu J, Zhao Y Y, Vogel S M, Malik A B (2006). Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J Immunol, 177(7): 4853–4860

Glenn J R Jr, Soppe D (1992). Sequence and expression of caveolin, a protein component of caveola plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci U S A, 89(21): 10517–10521

Han F, Gu D, Chen Q, Zhu H (2009). Caveolin-1 acts as a tumor suppressor by down-regulating epidermal growth factor receptor-mitogen-activated protein kinase signaling pathway in pancreatic carcinoma cell lines. Pancreas, 38(7): 766–774

Hashimoto M, Takenouchi T, Rockenstein E, Maslia E (2003). Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J Neurochem, 85(6): 1468–1479

Head B P, Insel P A (2007). Do caveolins regulate cell cycles by actions outside of caveolae? Trends Cell Biol, 17(2): 51–57

Hernández-Bello R, Bermúdez-Cruz R M, Fonseca-Liñán R, García-Reyna P, Le Guerhier F, Boireau P, Ortega-Pierryes G (2008). Identification, molecular characterisation and differential expression of caveolin-1 in Trichinella spiralis maturing oocytes and embryos. Int J Parasitol, 38(2): 191–202

Hino M, Doiha K, Kobayashi K, Aoe M, Shimizu N (2003). Caveolin-1 as tumor suppressor gene in breast cancer. Surg Today, 33(7): 486–490

Huang J H, Lu L, Lu H, Chen X, Jiang S, Chen Y H (2007). Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. J Biol Chem, 282(9): 6143–6152

Joshi B, Strugnell S S, Goetz J G, Kojic L D, Cox M E, Griffith O L, Chan S K, Jones S J, Leung S P, Masoudi H, Leung S, Wiseman S M, Nabi I R (2008). Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res, 68(20): 8210–8220

Juhász M, Chen J, Tullassay Z, Malferttheiner P, Ebert M P (2003). Expression of caveolin-1 in gastrointestinal and extraintestinal cancers. J Cancer Res Clin Oncol, 129(9): 493–497

Kasper M, Reimann T, Hempel U, Wenzel K W, Bierhaus A, Schuh D, Dimmer V, Haroske G, Müller M (1998). Loss of caveolin expression in type I pneumocytes as an indicator of subcellular alterations during lung fibrogenesis. Histochem Cell Biol, 109(1): 41–48

Kim H A, Kim K H, Lee R A (2006). Expression of caveolin-1 is correlated with Akt-1 in colorectal cancer tissues. Exp Mol Pathol, 80(2): 165–170

Kim Y N, Bertics P J (2002). The endocytosis-linked protein dynamin associates with caveolin-1 and is tyrosine phosphorylated in response to the activation of a noninternalizing epidermal growth factor receptor mutant. Endocrinology, 143(5): 1726–1731

Kogo H, Aiba T, Fujimoto T (2004). Cell type-specific occurrence of caveolin-1alpha and -1beta in the lung caused by expression of distinct mRNAs. J Biol Chem, 279(24): 25574–25581

Kogo H, Fujimoto T (2000). Caveolin-1 isoforms are encoded by distinct mRNAs. Identification of mouse caveolin-1 mRNA variants caused by alternative transcription initiation and splicing. FEBS Lett, 465(2–3): 119–123

Labrecque L, Royal I, Surprenant D S, Patterson C, Gingras D, Beliveau R (2003). Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell, 14(1): 334–347

Lavie Y, Fiucchi G, Liscovitch M (1998). Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem, 273(49): 32380–32383

Le Lan C, Neumann J M, Jamin N (2006). Role of the membrane interface on the conformation of the caveolin scaffolding domain: a CD and NMR study. FEBS Lett, 580(22): 5301–5305

Lee E K, Lee Y S, Han I O, Park S H (2007). Expression of Caveolin-1 reduces cellular responses to TGF-beta1 through down-regulating the expression of TGF-beta type II receptor gene in NIH3T3 fibroblast cells. Biochem Biophys Res Commun, 359(2): 385–390

Lee H, Volonte D, Galbiati F, Iyengar P, Lublin D M, Bregman D B, Wilson M T, Campos-Gonzalez R, Bouzahzah B, Pestell R G, Scherer P E, Lisanti M P (2000). Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol, 14(11): 1750–1775

Lee H, Woodman S E, Engelman J A, Volonte D, Galbiati F, Kaufman H L, Lublin D M, Lisanti M P (2001). Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (Tyr-14). J Biol Chem, 276(37): 35150–35158

Li L, Ren C, Yang G, Goltsov A A, Tabata K, Thompson T C (2009). Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res, 7(11): 1781–1791

Li S, Seitz R, Lisanti M P (1996). Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-src in vivo. J Biol Chem, 271(7): 3863–3868

Lin S, Wang X M, Nadeau P E, Mergia A (2010). HIV infection upregulates caveolin 1 expression to restrict virus production. J Virol, 84(18): 9487–9496

Linge A, Weinhold K, Blaβe R, Kasper M, Barth K (2007). Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells. Int J Biochem Cell Biol, 39(10): 1964–1974

Lisanti M P, Scherer P E, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu Y H, Cook R F, Sargiacomo M (1994). Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol, 126(1): 111–126

Liu J, Razani B, Tang S, Termman B I, Ware J A, Lisanti M P (1999). Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolar formation in vascular endothelial cells. J Biol Chem, 274(22): 15781–15785

Liu P, Rudick M, Anderson R G (2002). Multiple functions of caveolin-1. J Biol Chem, 277(44): 41295–41298

Llanos M, Kelly T, Vanegas M, Peretz M, Peterson T E, Simari R D, Poeschla E M (2002). Blockade of human immunodeficiency virus type 1 expression by caveolin-1. J Virol, 76(18): 9152–9164

Machleidt T, Li W P, Liu P, Anderson R G (2000). Multiple domains in caveolin-1 control its intracellular traffic. J Cell Biol, 148(1): 17–28
Macovei A, Radulescu C, Lazar C, Petrescu S, Durantel D, Dwek R A, Zitzmann N, Nichita N B (2010). Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells. J Virol, 84(1): 243–253.

Matthews L C, Taggart M J, Westwood M (2008). Modulation of caveolin-1 expression can affect signalling through the phosphatidylinositol 3-kinase/Akt pathway and cellular proliferation in response to insulin-like growth factor I. Endocrinology, 149(10): 5199–5208.

Mayoral R, Fernández-Martinez A, Roy R, Boscá L, Martin-Sanz P (2007). Dispensability and dynamics of caveolin-1 during liver regeneration and in isolated hepatic cells. Hepatology, 46(3): 813–822.

Mir K D, Parr R D, Schroeder F, Ball J M (2007). Rotavirus NSP4 interacts with both the amino- and carboxyl-termini of caveolin-1. Virus Res, 126(1–2): 106–115.

Mo S, Wang L, Li Q, Li J, Li Y, Thannickal V J, Cui Z (2010). Caveolin-1 regulates drosophila pattern formation through directly interaction with beta-catenin in zebraphish. Dev Biol, 344(1): 210–223.

Nixon S J, Carter A, Wegner J, Ferguson C, Floetenmeyer M, Riches J, Key B, Westerfield M, Parton R G (2007). Caveolin-1 is required for lateral line neuromast and notochord development. J Cell Sci, 120(Pt 13): 2151–2161.

Nohe A, Keating E, Underhill T M, Knaus P, Petersen N O (2005). Dynamics and interaction of caveolin-1 isoforms with BMP-receptors. J Cell Sci, 118(Pt 3): 643–650.

Nyström F H, Chen H, Cong L N, Li Y, Quon M J (1999). Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. Mol Endocrinol, 13(12): 2013–2024.

Ono K, Iwanaga Y, Hirayama M, Kawamura T, Sowa N, Hasegawa K (2004). Contribution of caveolin-1 alpha and Akt to TNF-alpha-induced cell death. Am J Physiol Lung Cell Mol Physiol, 287(1): L201–L209.

Padhan K, Tanwar C, Hussain A, Hui P Y, Lee M Y, Cheung C Y, Peiris M S, Wang L, Li Q, Li J, Li Y, Thannickal V J, Cui Z (2010). Caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry, 39(45): 13916–13924.

Razani B, Engelman J A, Wang X B, Schubert W, Zhang X L, Marks C B, Macaluso F, Russell R G, Li M, Pestell R G, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ G J, Edelmann W, Lisanti M P (2001b). Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem, 276(41): 38121–38138.

Razani B, Park D S, Miyanaga Y, Ghatpande A, Cohen J, Wang X B, Scherer P E, Evans T, Lisanti M P (2002). Molecular cloning and developmental expression of the caveolin gene family in the amphibian Xenopus laevis. Biochemistry, 41(25): 7914–7924.

Santibanez J F, Blanco F J, Garrido-Martin E M, Sanz-Rodriguez F, del Pozo M A, Bernabeu C (2008). Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae. Cardiovasc Res, 77(4): 791–799.

Scherer P E, Scherer P E, Zhang X L, Muñoz N, Galleguillos D, Leyton L, Quest A F (2009). Caveolin-1-mediated suppression of cyclooxygenase-2 via a beta-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression. Mol Biol Cell, 20(8): 2297–2310.

Sawada S, Ishikawa C, Tanji H, Nakachi S, Senba M, Okudaira T, Scherer P E, Lewis R Y, Volonte D, Engelman J A, Galbiati F, Couet J, Kohtz D S, van Donselaar E, Peters P, Lisanti M P (1995). Oligomeric structure of caveolin: implications for caveole membrane organization. Proc Natl Acad Sci USA, 92(20): 9407–9411.

Schwenecke C, Braun-Dullaeus R C, Wunderlich C, Strasser R H (2006). Caveolae and caveolin in transmembrane signaling: Implications for of insulin-like growth factor-I receptors and signaling. Oncogene, 24(8): 1338–1347.

Razani B, Altschuler Y, Zhu L, Pestell R G, Mostov K E, Lisanti M P (2000). Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression supresses HPV-mediated cell transformation. Biochemistry, 39(45): 13916–13924.

Razani B, Engelman J A, Wang X B, Schubert W, Zhang X L, Marks C B, Macaluso F, Russell R G, Li M, Pestell R G, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ G J, Edelmann W, Lisanti M P (2001b). Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem, 276(41): 38121–38138.

Razani B, Park D S, Miyanaga Y, Ghatpande A, Cohen J, Wang X B, Scherer P E, Evans T, Lisanti M P (2002). Molecular cloning and developmental expression of the caveolin gene family in the amphibian Xenopus laevis. Biochemistry, 41(25): 7914–7924.

Razani B, Zhang X L, Bitzer M, von Gersdorff G, Böttiger E P, Lisanti M P (2001a). Caveolin-1 regulates transforming growth factor-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem, 276(9): 6727–6738.

Rodriguez D A, Tapia J C, Fernandez J G, Torres V A, Muñoz N, Galleguillos D, Leyton L, Quest A F (2009). Caveolin-1-mediated suppression of cyclooxygenase-2 via a beta-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression. Mol Biol Cell, 20(8): 2297–2310.

Rothberg K G, Heuser J E, Donzell W C, Ying Y S, Glenney J R, Anderson R G (1992). Caveolin, a protein component of caveolae membrane coats. Cell, 68(4): 673–682.

Santibanez J F, Blanco F J, Garrido-Martin E M, Sanz-Rodriguez F, del Pozo M A, Bernabeu C (2008). Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae. Cardiovasc Res, 77(4): 791–799.

Sargentacomo M, Scherer P E, Tang Z, Kühler E, Song K S, Sanders M C, Lisanti M P (1995). Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc Natl Acad Sci USA, 92(20): 9407–9411.
human disease. Cardiovasc Res, 70(1): 42–49

Schlegel A, Lisanti M P (2000). A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo. J Biol Chem, 275(28): 21605–21617

Schubert W, Sotgia F, Cohen A W, Capozza F, Bonuccelli G, Bruno C, Minetti C, Bonilla E, Dimaruo S, Lisanti M P (2007). Caveolin-1 (-/-) and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation. Am J Pathol, 170(1): 316–333

Sedding D G, Braun-Dullaeus R C (2006). Caveolin-1: dual role for proliferation of vascular smooth muscle cells. Trends Cardiovasc Med, 16(2): 50–55

Smith J L, Campos S K, Ozbun M A (2007). Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol, 81(18): 9922–9931

Sun L, Hemgård G V, Susanto S A, Wirth M (2010). Caveolin-1 influences human influenza A virus (H1N1) multiplication in cell culture. Virol J, 7(1): 108

Sun X H, Flynn D C, Castranova V, Millecchia L L, Beardsley A R, Liu J (2007). Identification of a novel domain at the N terminus of caveolin-1 that controls rear polarization of the protein and caveole formation. J Biol Chem, 282(10): 7232–7241

Tamai O, Oka N, Kikuchi H, Shimizu F, Kimura H, Imaizumi T, Okuda S (2001). Caveole in mesangial cells and caveolin expression in mesangial proliferative glomerulonephritis. Kidney Int, 59(2): 471–480

Tang Z, Okamoto T, Boontrakulpoontawee P, Katada T, Otsuka A J, Lisanti M P (1997). Identification, sequence, and expression of an invertebrate caveolin gene family from the nematode Caenorhabditis elegans. Implications for the molecular evolution of mammalian caveolin genes. J Biol Chem, 272(4): 2437–2445

Torres V A, Tapia J C, Rodriguez D A, Parraga M, Lisboa P, Montoya M, Leyton L, Quest A F (2006). Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin. J Cell Sci, 119(Pt 9): 1812–1823

Tourtikina E, Richard M, Gööö P, Bonner M, Pannu I, Harley J, Bernechez P N, Sessa W C, Silver R M, Hoffman S (2008). Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol, 294(5): L843–L861

Uittenbogaard A, Smart E J (2000). Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae. J Biol Chem, 275(33): 25595–25599

Wang C, Mei Y, Li L, Mo D, Li J, Zhang H, Tian X, Chen Y (2008). Molecular characterization and expression analysis of caveolin-1 in pig tissues. Sci China C Life Sci, 51(7): 655–661

Wang L, Mo S, Li J, Li Q, Cui Z (2010a). Preliminary study on functions of zebrafish Caveolin-1. Acta Hydrobiologica Sinica, 34(4): 1083–1090

Wang X M, Kim H P, Song R, Choi A M (2006). Caveolin-1 confers antiinflammatory effects in murine macrophages via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol, 34(4): 434–442

Wang X M, Nadeau P E, Lo Y T, Mergia A (2010b). Caveolin-1 modulates HIV-1 envelope-induced bystander apoptosis through gp41. J Virol, 84(13): 6515–6526

Williams T M, Lisanti M P (2004). The Caveolin genes: from cell biology to medicine. Ann Med, 36(8): 584–595

Williams T M, Lisanti M P (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol, 288(3): C494–C506

Yamada E (1955). The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol, 1(5): 445–458

Yamaguchi Y, Yasuoka H, Stolz D B, Feghali-Bostwick C A (2010). Decreased caveolin-1 levels contribute to fibrosis and deposition of extracellular IGFBP-5. J Cell Mol Med, 14(6): 2160–2167

Yamamoto H, Komekado H, Kikuchi A (2006). Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell, 11(2): 213–223

Zaas D W, Swan Z, Brown B J, Wright J R, Abraham S N (2009). The expanding roles of caveolin proteins in microbial pathogenesis. Commun Integr Biol, 2(6): 535–537

Zhang B, Peng F, Wu D, Ingram A J, Gao B, Krepsinsky J C (2007). Caveolin-1 phosphorylation is required for stretch-induced EGFR and Akt activation in mesangial cells. Cell Signal, 19(8): 1690–1700

Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov K E, Pestell R G, Lisanti M P (2000). Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem, 275(27): 20717–20725

Zhao X, Liu Y, Ma Q, Wang X, Jin H, Mehrpour M, Chen Q (2009). Caveolin-1 negatively regulates TRAIL-induced apoptosis in human hepatocarcinoma cells. Biochem Biophys Res Commun, 378(1): 21–26

Zhu H, Cai C, Chen J (2004). Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. FEBS Lett, 576(3): 369–374